<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Clin. Invest</journal-id>
<journal-id journal-id-type="publisher-id">J Clin Invest</journal-id>
<journal-title-group>
<journal-title>The Journal of Clinical Investigation</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9738</issn>
<issn pub-type="epub">1558-8238</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29337302</article-id>
<article-id pub-id-type="pmc">5785268</article-id>
<article-id pub-id-type="publisher-id">95743</article-id>
<article-id pub-id-type="doi">10.1172/JCI95743</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Critical roles of <bold>α</bold>II spectrin in brain development and epileptic encephalopathy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yu</given-names>
</name>
<email>eegwang@med.umich.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ji</surname>
<given-names>Tuo</given-names>
</name>
<email>tuoji@med.umich.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nelson</surname>
<given-names>Andrew D.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Glanowska</surname>
<given-names>Katarzyna</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Murphy</surname>
<given-names>Geoffrey G.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jenkins</surname>
<given-names>Paul M.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parent</surname>
<given-names>Jack M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Neurology,</aff>
<aff id="A2"><label>2</label>Department of Pharmacology,</aff>
<aff id="A3"><label>3</label>Molecular and Behavioral Neuroscience Institute,</aff>
<aff id="A4"><label>4</label>Department of Molecular and Integrative Physiology, and</aff>
<aff id="A5"><label>5</label>Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA.</aff>
<aff id="A6"><label>6</label>Ann Arbor VA Healthcare System, Ann Arbor, Michigan, USA.</aff>
<author-notes>
<corresp>Address correspondence to: Jack M. Parent, Department of Neurology, University of Michigan, 5021 BSRB, 109 Zina Pitcher Place, Ann Arbor, Michigan 48109-2200, USA. Phone: 734.763.3776; E-mail: <email>parent@umich.edu</email>.</corresp>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2018-01-16T16:00:00-0500" publication-format="electronic">
<day>16</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date date-type="pub" iso-8601-date="2018-02-01T16:00:00-0500" publication-format="print">
<day>1</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>5</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 3 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>128</volume>
<issue>2</issue>
<fpage>760</fpage>
<lpage>773</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>6</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>11</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018, American Society for Clinical Investigation</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://www.jci.org/articles/view/95743">This article is available online at https://www.jci.org/articles/view/95743</self-uri>
<abstract>
<p>The nonerythrocytic α-spectrin-1 (<italic>SPTAN1</italic>) gene encodes the cytoskeletal protein αII spectrin. Mutations in <italic>SPTAN1</italic> cause early infantile epileptic encephalopathy type 5 (EIEE5); however, the role of αII spectrin in neurodevelopment and EIEE5 pathogenesis is unknown. Prior work suggests that αII spectrin is absent in the axon initial segment (AIS) and contributes to a diffusion barrier in the distal axon. Here, we have shown that αII spectrin is expressed ubiquitously in rodent and human somatodendritic and axonal domains. CRISPR-mediated deletion of <italic>Sptan1</italic> in embryonic rat forebrain by in utero electroporation caused altered dendritic and axonal development, loss of the AIS, and decreased inhibitory innervation. Overexpression of human EIEE5 mutant <italic>SPTAN1</italic> in embryonic rat forebrain and mouse hippocampal neurons led to similar developmental defects that were also observed in EIEE5 patient-derived neurons. Additionally, patient-derived neurons displayed aggregation of spectrin complexes. Taken together, these findings implicate αII spectrin in critical aspects of dendritic and axonal development and synaptogenesis, and support a dominant-negative mechanism of <italic>SPTAN1</italic> mutations in EIEE5.</p>
</abstract>
<kwd-group kwd-group-type="specialties">
<kwd>Development</kwd>
<kwd>Neuroscience</kwd>
</kwd-group>
<kwd-group kwd-group-type="keywords">
<kwd>Epilepsy</kwd>
<kwd>Genetic diseases</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>NIH</funding-source>
<award-id>1 K08 NS099379-01</award-id>
</award-group>
<award-group>
<funding-source>Pediatric Epilepsy Research Foundation</funding-source>
<award-id>Mechanistic Studies</award-id>
<award-id>Therapy Development for Epileptic Encephalopathies</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>